Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Caribou Biosciences (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Rachel Haurwitz, PhD, the company's president and CEO, will deliver a corporate update presentation on Thursday, January 16, 2025, at 10:30 am PST.
The presentation will be accessible via webcast through the Events page on Caribou's website, with recordings remaining available for 30 days following the event.
Positive
- None.
Negative
- None.
BERKELEY, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, is scheduled to present a corporate update at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 10:30 am PST.
For more information and a link to the live webcast, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for 30 days after the event.
About Caribou’s novel next-generation CRISPR platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”) that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its chRDNA technology to carry out high efficiency multiple edits, to develop CRISPR-edited therapies.
About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases. Follow us @CaribouBio and visit www.cariboubio.com.
Caribou Biosciences, Inc. contacts:
Investors:
Amy Figueroa, CFA
investor.relations@cariboubio.com
Media:
Peggy Vorwald, PhD
media@cariboubio.com
FAQ
When is Caribou Biosciences (CRBU) presenting at the 2025 J.P. Morgan Healthcare Conference?
How long will the CRBU J.P. Morgan Healthcare Conference webcast be available?
Who is presenting for CRBU at the 2025 J.P. Morgan Healthcare Conference?
Where can investors access CRBU's J.P. Morgan Healthcare Conference presentation?
